Overview

Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
Participant gender:
Summary
Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.
Phase:
Phase 2
Details
Lead Sponsor:
Central Institute of Mental Health, Mannheim
Collaborator:
University of Freiburg
Treatments:
Naltrexone